Powered 500 · 2026POWEREDS. 017 of 500
By building a cell-free DNA synthesis platform that produces longer, more accurate sequences faster and cheaper, Hill is dismantling one of biotech's most persistent R&D bottlenecks — with pharmaceutical and agricultural partners already signed on to prove it.
Matt Hill is Founder and CEO of Elegen, a synthetic biology company developing cell-free technologies for producing synthetic DNA on accelerated timelines.
Elegen's platform enables the construction of longer and more accurate DNA sequences for agriculture, chemicals, healthcare, and pharmaceuticals. Based in the San Francisco Bay Area, the company has attracted venture capital and partnerships with leading pharmaceutical and agricultural companies.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
